Ticker
$TENX
1 catalyst touching TENX in the last 60 days, newest first, each with the price move that followed.
- 55
Tenax pauses LEVEL-2 trial, refines enrollment based on Phase 3 results
Tenax temporarily paused enrollment in its LEVEL-2 clinical trial for TNX-103 and plans to amend enrollment criteria based on learnings from the recently completed Phase 3 LEVEL trial in PH-HFpEF. The company has also requested a Type C meeting with the FDA to discuss levosimendan development. This represents a trial strategy adjustment with potential regulatory dialogue, but lacks clarity on trial outcomes or FDA guidance impact.
TENX ·SEC 8-K · 8 Oct 2026, 20:15 UTC
Information only. AURA does not give buy or sell recommendations.